| Drug |
Therapeutic Area |
Action |
Disease / Condition |
Stage |
Estimated date |
Partner |
| Generic fondaparinux |
Cardiovascular |
Indirect factor Xa inhibitor |
VTE |
Marketed |
Launched; approved by FDA in July 2011 |
Dr Reddy’s |
| HA-Irinotecan |
Oncology |
Topoisomerase I inhibitor |
Colorectal Cancer |
Clinical - Ph III |
Recruitment commenced January 2012 |
|
| HA-Irinotecan |
Oncology |
Topoisomerase I inhibitor |
Small Cell Lung Cancer Stem Cells |
Clinical – Ph II Investigator- Sponsored Study |
Phase II Initiated September 2011 |
|
| VAST |
Neuroscience |
Opioid agonist |
Pain |
Discovery |
|
University of Queensland |
| VAST |
Respiratory |
Positive allosteric modulator |
Cronic Obstructive Pulmonary Disorder |
Discovery |
|
|
| VAST |
Multiple |
Varied |
Multiple |
Discovery |
Variety |
Multiple pharmaceutical pertners |
Discovery - chemical compounds with possible therapeutic benefit in man are identified
Preclinical - compound/treatments are tested to measure efficacy and safety prior to testing in humans
Clinical - structured studies are conducted in a hospital or clinic in which a drug is evaluated for its effects on humans
ASX Code: ACL
